UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003265
Receipt number R000001674
Scientific Title Prevention of myocardial injury with rosuvastatin during coronary intervention study
Date of disclosure of the study information 2010/02/28
Last modified on 2021/09/07 11:32:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prevention of myocardial injury with rosuvastatin during coronary intervention study

Acronym

PRIMITIVE study

Scientific Title

Prevention of myocardial injury with rosuvastatin during coronary intervention study

Scientific Title:Acronym

PRIMITIVE study

Region

Japan


Condition

Condition

Coronary Artery Disease

Classification by specialty

Medicine in general Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To Clarify the efficacy of high dose of rosuvastatin for suppression of myocardial injury during PCI

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

a) PCI related cardiac complication
b) elevation of the following cardiac markers
1) troponin T
2) N-terminal pro brain natriuretic peptide
3) CPK, CPK-MB
C) EKG change after PCI
D) no reflow or slow flow after PCI

Key secondary outcomes

a) any adverse events related to rosuvastatin
b) no reflow or slow reflow during PCI
c) PCI related non-cardiac complication
d) IVUS findings before PCI
e) Cardiac events or death after 3-year follow-up period


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Duration: from 5 - 10 days before PCI to the day of PCI
Drug: rosuvastatin 2.5 mg
Method: oral administration once a day

Interventions/Control_2

Duration: from 5 - 10 days before PCI to the day of PCI
Drug: rosuvastatin 10 mg
Method: oral administration once a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with coronary aretery disease undergoing PCI
2. dyslipidemia (T-CHO=>220 mg/dl, TG=>150 mg/dl, HDL-CHO<40 mg/dl, or LDL-CHO=>100mg/dl, or already treated with statin)
3. Patients who agree to participate in this study.

Key exclusion criteria

1. Patients with severe renal disease (sCR=>3.0, urine protein +++ urine OB +++) or liver disease (AST>100IU/l, ALT>100IU/l, T-bil>3.0mg/dl, PT<60%, albumin<2.8g/dl)
2. ACS patients who need to receive emergency revascularization
3. Patients with no-PCI indication lesion such as LMT
4. in-stent or para-stent restenosis
5. Patients who cannot take statin
6. malignancy

Target sample size

400


Research contact person

Name of lead principal investigator

1st name Kyoichi
Middle name
Last name Mizuno

Organization

Nippon Medical School

Division name

Department of Medicine

Zip code

113-8602

Address

1-1-5, Sendagi, Bunkyo, Tokyo, Japan

TEL

0338222131

Email

htakano@nms.ac.jp


Public contact

Name of contact person

1st name Hitoshi
Middle name
Last name Takano

Organization

nippon Medical School

Division name

Department of Medicine

Zip code

113-8602

Address

1-1-5, Sendagi, Bunkyo, Tokyo, Japan

TEL

0338222131

Homepage URL


Email

htakano@nms.ac.jp


Sponsor or person

Institute

Nippon Medical School

Institute

Department

Personal name



Funding Source

Organization

Nippon Medical School
Department of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nippon Medical School

Address

1-1-5, Sendagi, Bunkyo, Tokyo, Japan

Tel

0338222131

Email

htakano@nms.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本医科大学付属病院(東京都)
日本医科大学千葉北総病院(千葉県)
日本医科大学多摩永山病院(東京都)
日本医科大学武蔵小杉病院(神奈川県)
博慈会記念総合病院(東京都)
国立医療センター静岡病院(静岡県)


Other administrative information

Date of disclosure of the study information

2010 Year 02 Month 28 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/23507709/

Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/23507709/

Number of participants that the trial has enrolled

232

Results

The incidence of periprocedural MI did not significantly differ between the high and low-dose groups (8.7% vs 18.7%, p = 0.052). In patients who were not taking statins at the time of enrollment, high-dose rosuvastatin significantly suppressed periprocedural MI compared with the low dose. The difference was not significant in patients who were already taking statins .

Results date posted

2021 Year 09 Month 07 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2013 Year 05 Month 16 Day

Baseline Characteristics

CAD patients undergoing PCI

Participant flow

Prospective

Adverse events

None

Outcome measures

Preprocedural myocardial injury

Plan to share IPD

none

IPD sharing Plan description

none


Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 09 Month 09 Day

Date of IRB

2008 Year 08 Month 28 Day

Anticipated trial start date

2008 Year 09 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry

2012 Year 08 Month 01 Day

Date trial data considered complete

2012 Year 10 Month 01 Day

Date analysis concluded

2012 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 02 Month 28 Day

Last modified on

2021 Year 09 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001674


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name